Pictet Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19M Sell
395,861
-88,489
-18% -$3.8M 0.02% 541
2026
Q1
$17.8M Buy
+484,350
New +$22.9M 0.02% 518
2024
Q4
Sell
-192,948
Closed -$23M 2074
2024
Q3
$23M Buy
192,948
+763
+0.4% +$102K 0.03% 456
2024
Q2
$27.4M Sell
192,185
-51,098
-21% -$6.77M 0.03% 392
2024
Q1
$31.2M Buy
243,283
+234,683
+2,729% +$27.9M 0.03% 390
2023
Q4
$890K Buy
+8,600
New +$850K ﹤0.01% 1022

Other funds holding NVO

Pictet Asset Management's NVO Position: Q2 2026 in Review

Pictet Asset Management reduced its Novo Nordisk (NVO) stake by 18% in Q2 2026, selling an estimated $3.8M and leaving 395,861 shares worth $19M. The position accounts for 0.02% of the portfolio, ranked #541.

Pictet Asset Management first reported a position in NVO in Q4 2023 and has held it in 6 quarters since. The position peaked at $31.2M in Q1 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Pictet Asset Management held 395,861 shares of Novo Nordisk worth $19M as of Q2 2026.
  • Pictet Asset Management sold 88,489 Novo Nordisk shares in Q2 2026, an estimated $3.8M.
  • Novo Nordisk made up 0.02% of Pictet Asset Management's portfolio in Q2 2026, its #541 holding.
  • Pictet Asset Management first reported a position in Novo Nordisk in Q4 2023 and has held it in 6 quarters since.
  • Pictet Asset Management's Novo Nordisk position peaked at $31.2M in Q1 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.